These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 26597462

  • 1. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
    Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM.
    Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
    [Abstract] [Full Text] [Related]

  • 2. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Vermeulen RFM, Beurden MV, Kieffer JM, Bleiker EMA, Valdimarsdottir HB, Massuger LFAG, Mourits MJE, Gaarenstroom KN, van Dorst EBL, van der Putten HWHM, Aaronson NK.
    Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
    [Abstract] [Full Text] [Related]

  • 3. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
    Terra L, Beekman MJ, Engelhardt EG, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de Hullu JA, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, van de Beek I, Berger LPV, van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Aaronson NK, Mourits MJE, van Leeuwen FE.
    Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy.
    Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA.
    Gynecol Oncol; 2016 Jan; 140(1):95-100. PubMed ID: 26545955
    [Abstract] [Full Text] [Related]

  • 5. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
    Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM.
    Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
    [Abstract] [Full Text] [Related]

  • 6. Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.
    Johansen N, Liavaag AH, Mørkrid L, Michelsen TM.
    Sex Med; 2018 Jun; 6(2):143-153. PubMed ID: 29631858
    [Abstract] [Full Text] [Related]

  • 7. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C, Lyon L, Conell C, Littell RD, Powell CB.
    Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
    [Abstract] [Full Text] [Related]

  • 8. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    Grandi G, Sammarini M, Cortesi L, Toss A, Botticelli L, Varliero F, Sighinolfi G, Barbieri E, Facchinetti F.
    Menopause; 2021 Feb 01; 28(3):263-270. PubMed ID: 33534430
    [Abstract] [Full Text] [Related]

  • 9. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
    Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C, Izatt L, Tripathi V, Esteban I, McNicol L, Ragupathy K, Crawford R, Evans DG, Legood R, Menon U, Manchanda R.
    BJOG; 2021 Mar 01; 128(4):714-726. PubMed ID: 32803845
    [Abstract] [Full Text] [Related]

  • 10. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
    Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T.
    Psychooncology; 2020 Feb 01; 29(2):331-338. PubMed ID: 31654466
    [Abstract] [Full Text] [Related]

  • 11. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
    Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, Slart RH, van der Veer E, de Bock GH, Mourits MJ.
    Eur J Cancer; 2015 Feb 01; 51(3):400-8. PubMed ID: 25532426
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer.
    Heiniger L, Butow PN, Coll J, Bullen T, Wilson J, Baylock B, Meiser B, Price MA.
    Fam Cancer; 2015 Mar 01; 14(1):105-15. PubMed ID: 25283514
    [Abstract] [Full Text] [Related]

  • 13. Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
    Tucker PE, Saunders C, Bulsara MK, Tan JJ, Salfinger SG, Green H, Cohen PA.
    Breast; 2016 Dec 01; 30():26-31. PubMed ID: 27592287
    [Abstract] [Full Text] [Related]

  • 14. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
    Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA.
    Maturitas; 2016 Mar 01; 85():42-8. PubMed ID: 26857878
    [Abstract] [Full Text] [Related]

  • 15. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
    Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA.
    Int J Gynecol Cancer; 2009 Aug 01; 19(6):1029-36. PubMed ID: 19820364
    [Abstract] [Full Text] [Related]

  • 16. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
    Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK.
    J Clin Oncol; 2006 Aug 01; 24(22):3576-82. PubMed ID: 16877724
    [Abstract] [Full Text] [Related]

  • 17. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis.
    Wei X, Oxley S, Sideris M, Kalra A, Brentnall A, Sun L, Yang L, Legood R, Manchanda R.
    Am J Obstet Gynecol; 2023 Oct 01; 229(4):388-409.e4. PubMed ID: 37059410
    [Abstract] [Full Text] [Related]

  • 18. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
    Michelsen TM, Dørum A, Dahl AA.
    Gynecol Oncol; 2009 Apr 01; 113(1):128-33. PubMed ID: 19178933
    [Abstract] [Full Text] [Related]

  • 19. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas AHEM, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van Doorn HC, Mourits MJE, van Beurden M, Zweemer RP, Gaarenstroom KN, Slangen BFM, Brood-van Zanten MMA, Vos MC, Piek JMJ, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, Massuger LFAG, IntHout J, Hermens RPMG, de Hullu JA.
    JAMA Oncol; 2021 Aug 01; 7(8):1203-1212. PubMed ID: 34081085
    [Abstract] [Full Text] [Related]

  • 20. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    Gaba F, Manchanda R.
    Best Pract Res Clin Obstet Gynaecol; 2020 May 01; 65():46-65. PubMed ID: 32192936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.